The North America TB diagnostics market size is expected to reach a valuation of USD 905.08 million by 2030, growing at a CAGR of 5.66% during the forecast period (2022-2030).
Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections proceed to active illness, which kills about half of individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.
The bacteria Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.
One of the primary drivers driving market growth is the high prevalence of TB in the region, as well as favourable health-care policies. According to the World Economic Forum, North America has a robust economy, accounting for 27.95% of global GDP, which is one of the elements influencing the healthcare sector. When comparing the two countries, the US spends more on healthcare than Canada. Additionally, the industry is being driven by greater rise in expenditure for private hospital care, physician, health insurance, and clinical services. Furthermore, the need for TB diagnosis tools and medicines is reflected in healthcare and public spending, which serves as a key driver for this market.
Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread.
North America TB diagnostics market is mostly focused on those aged 60 and over, as this group is more susceptible to infectious infections. The growing geriatric population base, which is contributing to the global TB diagnostics market's growth.
To combat the spread of TB, private and public healthcare institutions are launching programmes. Increasing diagnosis and screening rates by raising knowledge about the importance of diagnosis is assisting the worldwide TB diagnostics market to expand at a significant rate over the forecast period.
The focus of development is on increasing screening rates, sophisticated techniques, diagnostic affordability, mortality reduction, and speedier clinical judgments. These approaches have resulted in higher rates of curative and preventative diagnosis. As a result, demand for diagnostic tests has increased, resulting in the worldwide North America TB diagnostics market expanding.
During the projection period, the high cost of testing techniques and the need for specialised instruments for testing are projected to limit the worldwide TB testing market's growth.
TB testing market is likely to be restrained in North America by compromised accuracy and longer processing times over the forecast period.
By type the market is divided into Sputum smear microscopy, culture-based diagnostics, fast molecular diagnostics, and others are the several types of diagnostics available. The market is divided into two types of end-users: hospitals and diagnostic labs. The market is divided into five regions: North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
The quick molecular diagnostics category held most of the worldwide market for TB diagnostics. The fact that it is one of the most accurate test kinds in these diagnostics accounts for a large part of the market. During the analysis period, new product introductions for the quick molecular diagnostics market are expected to fuel the segment's growth.
The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, for example, announced the launch of the innovative Expert MTB/XDR test in July 2020, which enables for extended drug-resistance tuberculosis (TB) profiling in less than 90 minutes.
For the laboratory diagnosis of this condition, culture-based diagnostics was thought to be the gold standard. Due to the rising prevalence of this illness and related ailments throughout the world, the category will generate significant market revenue over the forecast period. However, the demand for culture-based assays has decreased in recent years due to the emergence of quick molecular diagnostics.
In 2020, the diagnostic labs category accounted for the largest market share by end user. The enormous number of diagnostic procedures performed in this area is one of the reasons for its dominance.
These establishments There were roughly 29,227 diagnostic and medical laboratories in the United States as of May 2021. The existence of a high number of these institutions in major nations like the United States is projected to help the market grow.
Hospitals maintained a significant market share. The segment is expected to increase at a high rate because of the large number of TB diagnostic procedures performed in hospitals.
In 2020, North America had a market share of USD 0.56 billion in global tuberculosis (TB) diagnostics, which is expected to expand significantly through 2028. The economically stable and well-informed populace is responsible for the region's growth. The regional picture will be aided by a well-established healthcare system and extensive acceptance of technologically improved items.
North America is anticipated to be the largest market for TB diagnostics by 2030, with a market value of USD 905.08 million and a CAGR of 5.66%. The robust regional market may be attributed to the increased demand for sophisticated healthcare and the use of technology and novel tests for diagnosis, treatment, care, rehabilitation, and overall healthcare improvement. Increased research and development investment for better TB diagnostics is projected to boost the tuberculosis diagnostics market.
In 2020, the North American market was worth USD 0.56 billion. The adoption of comparably technologically advanced and high-cost healthcare solutions in major nations such as the United States and the highly knowledgeable and economically stable population in key countries such as the United States have given the area a robust share.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
The new Xpert MTB/XDR test, developed by the Foundation for Innovative New Diagnostics (FIND) and Cepheid Inc., allows for extended drug-resistance tuberculosis (TB) profiling in less than 90 minutes.
May 2020: Thermo Fisher Scientific announced the USD 11.5 billion acquisition of Qiagen, a molecular diagnostic focused firm. Using Qiagen's QuantiFeron-TB Gold Plus latent tuberculosis detection test, the QiaSymphony platform for molecular diagnostics infectious disease testing, and the QiaStart-Dx syndromic testing system, the acquisition aims to advance the portfolio in precision medicine by increasing focus on infectious diseases, cancer, and genetic disorders.